Jackson · Seed–Growth · 10 people tracked
Also known as ALTA PARTNERS INVESTMENT MANAGER, L.P. · ALTA PARTNERS MANAGEMENT COMPANY, L.P. · Alta Partners NextGen
Find your way into Alta Partners
678 people in our graph share verified history with the Alta Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Alta Partners believes the healthcare sector has reached an inflection point where technology and innovation enable greater integration among physicians, payers, and patients to deliver better outcomes. The firm holds that healthcare should ultimately serve patients, and it is dedicated to supporting entrepreneurs in building high-impact companies. Its portfolio and outcomes center on life sciences and biotechnology, including cell and gene therapies, precision medicines, and clinical-stage biopharmaceutical companies.
Source: firm website, verified Sep 15, 2026.
Team · 10 people
from the firm's website & curated & public directories
What they invest in
from 43 of 69 portfolio companiesHealthtech ×28Biotech ×24Medical Devices ×12Digital Health ×10AI & Machine Learning ×6Enterprise Software ×4Fintech ×4SaaS ×4
HQs:United States×37
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×112 founders×33 founders×1
Where their founders worked beforefrom 10 founders with career history
New York Genome Center ×2
Investments · 69 tracked
founders shown can be your intro pathBy year:2025 · 52024 · 52023 · 12022 · 22019 · 32018 · 12017 · 22016 · 32015 · 32014 · 32012 · 129 dated
TransMedics develops and sells the Organ Care System (OCS), a portable warm perfusion platform for preserving and assessing donor hearts, lungs, and livers outside the body prior to transplantation, along with the National OCS Program, an end-to-end organ procurement and logistics service for transplant centers that includes aircraft and ground transportation.
HealthtechAndover, US
Waleed H. Hassanein(Executive Officer, Director)inStephen Gordon(Executive Officer)
BoardEdwin M. Kania, Jr.(Director)David Abrams(Director)Joseph S. Lacob(Director)Travis Rhodes(Director)
Co-investorsFlagship Pioneering
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsBioBritNextech InvestCanaan PartnersNEXTECH ONCOLOGY SCSPRA Capital
Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Marianne De Backer(CEO)inHerbert Virgin(Executive Officer)Howard Horn(Executive Officer)inAlex Bangs(Executive Officer)in
BoardGeorge Scangos(Executive Officer, Director)Vicki Sato(Director)
Co-investorsARCH Venture PartnersSoftBank Vision Fund8VCSoftBank Group
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardJohn McKearn(Director)inPeter Moldt(Director)
Board seatDan JanneyFarah Champsi· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapitalRoche Venture Fund
Berkeley, US
Peter Calthorpe(Executive Officer, Director)in
Board seatGarrett Gruener· per SEC Form D · $2M raise · filed Jul 2019
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
Board seatDan Janney· per SEC Form D · $11.3M raise · filed Aug 2017
Co-investorsAvoro Capital AdvisorsFrazier Life Sciences
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)in
Board seatDan Janney· per SEC Form D
Co-investorsLongwood FundMission BiocapitalService Provider CapitalDolby Family VenturesForbion
Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units.
BiotechHealthtechMedical DevicesCity Of Industry, US
Scott Elster(Executive Officer, Director)inJohn M. Shields(Executive Officer)in
BoardFrank Foster(Director)Martin Sutter(Director)David Brailer(Director)
Board seatDan Janney· per SEC Form D
Co-investorsAisling CapitalEssex Woodlands Healthcare PartnersFrontier Venture CapitalPROOF
Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Hugo Peris(Founder & CEO)inEugene de Juan(Executive Officer, Director)Lawrence Fritz(Director)
BoardWARREN THALER(Director)JEAN-FREDERIC PAULSEN(Director)
Board seatGuy Nohra· per SEC Form D · $10.9M raise · filed Feb 2023
Co-investorsCatalio Capital ManagementCamden PartnersEsperante VenturesInveready Technology Investment Group
USGI Medical develops endoluminal medical devices that enable surgical procedures without incisions, targeting healthcare providers and patients seeking less invasive treatment options.
HardwareHealthtechMedical DevicesSan Clemente, US
Tracy Maahs(Executive Officer)inScott Moonly(Executive Officer, Director)inJohn Cox(Executive Officer)in
BoardMike Chuisano(Director)George Abi-Chahine(Director)
Board seatGuy Nohra· per SEC Form D · $4M raise · filed Jun 2019
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAvoro Capital AdvisorsForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
Amplitude Therapeutics is a biotechnology company developing RNA-based medicines.
Biotech
Ark provides a customizable digital platform for venture capital and private equity firms to manage investor communications, performance reporting, and document sharing with their limited partners.
Enterprise SoftwareFintechSaaS
Co-investorsAcies InvestmentsAloft VCAmity VenturesArtis VenturesAsymmetric Capital PartnersAt One Ventures+21 more
Boston, US
Dan Adams(Executive Officer, Director)
BoardPete Hudson(Director)inBruce Herzfelder(Director)Mark Prather(Director)
Bioventus develops and markets medical devices for active healing, including pain management, restorative therapies, and surgical solutions that aim to enhance the body's natural healing processes and reduce the need for invasive procedures.
BiotechDeep TechHealthtechMedical DevicesDurham, US
Robert Claypoole(Chief Executive Officer)
Co-investorsAmpersandEssex Woodlands Healthcare Partners
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAisling CapitalAsset Management CompanyCanaan PartnersFrazier Life SciencesPappas CapitalSanderling Ventures
BiotechSan Carlos, US
Anthony P. Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)in
BoardRon Hunt(Director)inLoretta Tse, Ph.D.(Director)
Co-investorsNew Leaf Venture Partners
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)in
Co-investorsAstellas Venture Management LLCDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
DispatchHealth delivers in-home medical care and house call services, offering patients an alternative to emergency rooms and urgent care facilities for acute medical conditions.
Digital HealthHealthtechDenver, US
Dr. Mark Prather(Founder)Kevin Riddleberger(Founder)inDominic Bagnoli(Director)
BoardPete Hudson(Director)in
Co-investorsEcho Health VenturesOak HC/FTOptum VenturesQuesta CapitalSINEWAVE VENTURES
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class treatment candidate for hematologic malignancies and genetically-defined solid tumors.
BiotechHealthtechMedical Devices
Yinon Ben-Neriah(Scientific Founder)David N. Cook(Chief Executive Officer)inZung Thai(Chief Medical Officer)in
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAltium CapitalEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPKhosla VenturesOUP (Osage University Partners)b2ventureKendall Capital Partners+1 more
BiotechAnn Arbor, US
Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)
PartnerDan Janney· led
Co-investorsAisling CapitalArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan PartnersLongitude Capital+2 more
Everside is a venture capital and investment firm that manages portfolios and provides investment operations, analytics, and advisory services.
Enterprise SoftwareFintechSector Agnostic
Moritz Poehl(Founder, Managing Partner)inNate Kirk(Founder, Managing Partner)in
Co-investorsInterplay Ventures Early Stage Management LlcEndeavor CatalystNew Enterprise Associates (NEA)Oak HC/FT
Marathon Health provides advanced primary care combined with lifestyle and chronic condition management for employers and health plans, using health coaches and registered dietitians alongside providers.
Digital HealthHealthtechWellness & Fitness
Dr. Jeff Wells(Founder)
Co-investorsNew Enterprise Associates (NEA)Sixty Degree CapitalEndeavor CatalystOak HC/FT
Free Market Health operates a care-driven marketplace platform for the specialty pharmacy ecosystem.
B2B MarketplacesHealthtechSaaSPittsburgh, US
Joe Cardosi(Founder)in
Co-investorsQuesta Capital
Harbor provides electronic data capture (EDC) software for clinical trial teams, designed to reduce data entry time and enable remote monitoring to improve data quality and accelerate trial timelines.
HealthtechMedical DevicesSaaSSan Francisco, US
Albert Cai(Founder)inNathan H. Leung(Founder)in
Co-investorsY Combinator8VCDFOGeneral Catalyst
.png)
Harbor Plan provides automation software for independent professionals to manage their practices.
AI & Machine LearningFintechSaaSSales TechSan Francisco, US
Clinton A.(Managing Director)inRob Carrington(Head of Engineering)in
Co-investorsTechstarsTinySeed8VCDFOGeneral Catalyst
Crypto & Web3Enterprise SoftwareFintechSioux Falls, US
Co-investorsAndreessen HorowitzFuture Perfect VenturesKindred VenturesPantera Capital8VCBerggruen Holdings+3 more
Harbor provides sleep training and infant care services for parents and families seeking better sleep and wellness support.
AI & Machine LearningConsumerHardwareHealthtechIoTWellness & Fitness
Kelly Brown(Director of Nursing)Lindsey Sullivan(Chief Marketing Officer)
Co-investorsCarnrite Ventures8VCDFOGeneral CatalystTrust Ventures
Harbor Health is a healthcare provider and insurance company operating clinics across Texas that offers primary care, specialty care, and health coaching alongside integrated insurance coverage.
HealthtechInsurTechAustin, US
Sterling Claiborne Johnston(Chief Medical Officer)Jeffrey Fisher(Chief Financial Officer)Eric Scott(Vice President)inKara Rios(Chief Financial Officer)in
BoardPete Hudson(Director)inAnthony Miller(Director)in
Co-investors8VCHealth2047 Capital Partners LLCLemhi VenturesMartin VenturesBreyer CapitalCubit Capital+2 more
Kelonia is a biotechnology company developing next-generation genetic medicines, with a focus on cell and gene therapy programs including in vivo approaches and oncology applications.
BiotechHealthtech
Kevin Friedman(Founder & Chief Executive Officer)in
Co-investorsHorizons Ventures
Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells.
BiotechHealthtechSanta Monica, US
Arie S. Belldegrun(Executive Officer, Director)inMargo R. Roberts(Executive Officer)Cynthia Butitta(Executive Officer)inMarc Better(Executive Officer)inRizwana Sproule(Executive Officer)in
BoardJoshua A. Kazam(Director)
Co-investorsPontifax Venture Capital
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value FundCatalio Capital Management+2 more
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsCerity Partners Ventures5AM VenturesAlexandriaDCVC (Data Collective)DCVC Bio
Digital HealthHealthtechWellness & Fitness
PatientsLikeMe is a digital health platform where over 850,000 members with various health conditions share experiences and insights to help each other manage their health.
Digital HealthHealthtechSocialCambridge, US
Philippe Amouyal(Director)Jonathan White(Director)Justin Barstein(Director)Martin Coulter(Executive Officer, Director)Jay M. Tenenbaum(Director)Stephen Heywood
Co-investorsOptum Ventures
Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.
Co-investorsARCH Venture PartnersLAVSequoia Capital
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions to help people navigate the healthcare system and access on-demand care.
AI & Machine LearningDigital HealthHealthtech
Co-investorsThreshold VenturesAlly Bridge GroupGeneral CatalystGeodesic CapitalHuman CapitalKinnevik+2 more
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions into a single member experience, helping people navigate the healthcare system and access on-demand care.
AI & Machine LearningDigital HealthHealthtechDenver, US
Glen Tullman(Chief Executive Officer)in
Co-investors7wire VenturesCorewell Health VenturesGeneral CatalystGeodesic CapitalGreatPoint VenturesHuman Capital+5 more
UMP is a musculoskeletal (MSK) managed service organization that partners with independent physicians to handle administrative operations while preserving clinical autonomy.
Digital HealthEnterprise SoftwareHealthtechAtlanta, US
Raj Bholé(Founding Physician Director)
Co-investorsWCAS
Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.
AI & Machine LearningBiotechDigital HealthNew York, US
Kaja Wasik(Executive Officer, Director)inAndrew Farnum(Chief Executive Officer)inStephane Castel(Co-Founder, Chief Scientific & Technology Officer)inCraig Basson(Chief Medical Officer, President of R&D)inHolly Vance(Chief Operating Officer)in
BoardJulie Sunderland(Director)
Co-investorsGeneral CatalystLux CapitalSoftBank Vision FundDimension Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Carbylan TherapeuticsKelonia TherapeuticsVertiFlexAlly TherapeuticsAmplitude Therapeutics, Inc.BE BiopharmaBebiopharmaCellective TherapeuticsCoTherixCuteraDEM BioFlamel TechnologiesFoldRx PharmaceuticalsGenePeeksILEX OncologyImmuneIDImmuneidrxInterMune PharmaceuticalsKeloniaKosan BiosciencesMBraceProgentosSwedish Orphan Biovitrum (Sobi)U3 PharmaUnited Musculoskeletal Partners Holdings
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 9
3 IPOs · 6 acquisitionsTransMedicsNASDAQ: TMDXTYRA BiosciencesNASDAQ: TYRAVirNASDAQ: VIRCellective Therapeuticsacq. by MedImmuneHarboracq. by BitGoInterMune Pharmaceuticalsacq. by RocheKosan Biosciencesacq. by Bristol Myers SquibbPaladinahealthacq. by Marathon HealthU3 Pharmaacq. by Daiichi Sankyo
Portfolio news
latest coverage across their companiesBioventus · gurufocus.com · Sep 17, 2026
TransMedics · prnewswire.com · Aug 31, 2026
Vir · americanbankingnews.com · Aug 27, 2026
TYRA Biosciences · stocktitan.net · Aug 14, 2026
Harbor · kiiitv.com · Jul 17, 2026
Harbor · kiiitv.com · Jul 17, 2026
Harbor · kiiitv.com · Jul 17, 2026
Fund performance · per public LP disclosures · 7
as of Sep 2024| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Alta Partners VIIILPs: Employees' Retirement System of Rhode Island, Hawaii Employees' Retirement System | 2006 | — | 16.3% | 2.47x | 2.47x |
| Alta BioPharma Partners IIILPs: Employees' Retirement System of Rhode Island | 2003 | — | 5.8% | 1.50x | 1.42x |
| Alta BioPharma Partners II, L.P.LPs: California Public Employees' Retirement System | 2000 | — | 3.2% | 1.18x | 0.96x |
| Alta Subordinated Debt Partners IIILPs: The Regents of the University of California | 1993 | — | 28.8% | 3.40x | 3.40x |
| Alta Subordinated Debt Partners IILPs: The Regents of the University of California | 1988 | — | 12.1% | 2.12x | 2.12x |
| Alta Subordinated Debt PartnersLPs: The Regents of the University of California | 1986 | — | 8.6% | 1.88x | 1.88x |
| Alta Co PartnersLPs: The Regents of the University of California | 1980 | — | 13.6% | 2.22x | 2.22x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| TYRA Biosciences | 9.6% | $16.00 | Sep 2021 | $62.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Alta Partners made?
- Alta Partners has 69 tracked investments, 9 of which have exited, including 5 dated in the last 24 months.
- What stage does Alta Partners invest at?
- Alta Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Alta Partners's typical check size?
- Alta Partners typically writes checks of $1M – $12M.
- What sectors does Alta Partners focus on?
- Alta Partners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Alta Partners located?
- Alta Partners is headquartered in Jackson, US.
- Who does Alta Partners co-invest with?
- Alta Partners most often shares deals with ARCH Venture Partners, Longwood Fund, DC Investment Partners, among 82 tracked co-investors.
Media · Podcasts & interviews
featuring the teamPete Hudson, Alta Partners & Transcarent Investor, Part 1
The Health Care Blog's Channel · Pete Hudson
Jean Deleage - Alta Partners 2 5 2000
FRENCH AMERICAN TV ARCHIVES · Jean Deleage · youtube.com
Images
Co-investors · 17
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
Questa Capital is a venture capital firm that partners with teams building next-generation healthcare companies focused on improving patient outcomes and reducing costs.
Insight Partners is an investment firm focused on accelerating revenue and profit growth in software companies, providing capital and operational support through its Insight Onsite team.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
S32 is a high-conviction venture firm that concentrates on a small set of core relationships, committing deeply and supporting founders over the long term.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
▶5 more co-investors
Astellas Venture Management LLCUnknown VenturesPolaris PartnersDomain AssociatesAsset Management Ventures
Firms observed investing alongside Alta Partners, from public investor directories. Shared companies are the overlap with Alta Partners's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Gore Range Capital is a specialized healthcare investment firm building science-led platforms across precision health, regenerative medicine, personalized therapeutics, and longevity. It provides strategic, financial, and clinical guidance to portfolio companies developing next-generation healthcare solutions.